Thus, the isostere induced adjustment of the hydrogen bond network altered the structure and dynamics of A q /glycopeptide complexes leading to the loss of A q affinity and subsequent T cell response.
Introduction
Rheumatoid arthritis (RA) is an autoimmune disease that mainly affects peripheral joints by causing inflammation that destroys cartilage and bone. The cause of the disease is not yet known, but a genetic link has been found to the expression of the class II major histocompatibility complex (MHC) proteins HLA-DR1 and -DR4. 1 In collagen-induced arthritis (CIA), a validated mouse model for studies of RA, 2 development of disease is linked to expression of A q MHC II molecules. 3 Class II MHC proteins are found in antigen presenting cells (APC) where they are associated with peptides derived from endocytosed protein antigens. The complexes are then transported to the surface of the APC and presented to T-cell receptors (TCR) on circulating CD4 + T-cells, leading to initiation of an immune response towards the original antigen. CII259-273 1 (Fig. 1 ) -a glycopeptide fragment derived from type II collagen -is presented to CD4 + T-cells by A q MHC molecules in CIA. 4 Glycopeptide 1 has also been proven to work as a vaccine that effectively prevents development of disease in CIA when administered as a complex with A q . 5 The complex also reduces disease progression and severity in a mouse model of chronic relapsing arthritis. 5 In humans, glycopeptide 1 binds to DR4 and the complex is recognized by T-cells isolated from patients suffering from severe RA, suggesting 1 to have a central role in RA just as in CIA. 6 The minimal epitope in 1 required for binding to A q , and stimulation of CII restricted T cell hybridomas obtained in CIA, consists of amino acid residues Ile 260 -Gln 267 . 7 Antigenic peptides bind between the α 1 -and β 1 -helices of class II MHC proteins † Electronic supplementary information (ESI) available: RMSD for the α 1 helix vs. simulation time, RMSD for the β 1 helix vs. simulation time, RMSD for the β-sheet of the α 1 β 1 domain vs. simulation time, the number of frames occupying each cluster for the MD simulations, superposition of frames from the cluster analysis displaying the glycopeptide/A q complex, super-through a hydrogen bond network and by anchoring of sidechains in pockets in the binding groove. 8 Synthesis and biological evaluation of a comprehensive panel of synthetic analogues of 1 has revealed Ile 260 and Phe 263 to be crucial anchor residues that bind in hydrophobic pockets of A q ( Fig. 2) . 9, 10 Moreover, the galactosylated hydroxylysine at position 264 protrudes out of the binding site and is recognized by the TCR with exquisite specificity.
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Modification of glycopeptides, through the incorporation of amide bond isosteres, has been used to probe molecular interactions in the MHC/glycopeptide/TCR system. [12] [13] [14] [15] [16] [17] For instance, aza-amino acids, 15 (E)-alkene and ethylene isosteres 13 and oxazole modifications 12 have been employed. The Ile 260 -GalHyl 264 fragment of glycopeptide 1 has been the target for the majority of these modifications as it contains essential features, such as the two MHC anchor residues 9 and the galactose moiety crucial for TCR recognition. 4, 11 Incorporation of isosteres into 1 revealed the importance of having an intact network of hydrogen bonds for the stability of the complex with A q . 13 Furthermore, the dynamics of the complex were found to govern the response from the TCR; complexes that were more rigid than those of A q and 1 resulted in weaker T cell responses. 10, 13 In this study, we further explore the molecular interactions in the MHC/glycopeptide/TCR system that are crucial for the development of CIA, and most likely also for RA, by synthesis and evaluation of two additional amide bond isosteres incorporated into glycopeptide 1.
Results

Amide bond isosteres
Hydroxyethylene isosteres were selected for incorporation at the Ala 261 -Gly 262 position into glycopeptide 1 (Fig. 1 , compounds 2 and 3). The choice of isosteres and their location were based on previous investigations, where we explored replacement of this amide bond with ketomethylene, methyleneamine and (E)-alkene isosteres. 14 Evaluation of these glycopeptides showed that only ketomethylene-isostere modified glycopeptide 4 displayed comparable affinity for A q and T-cell responses to 1, whereas both binding and cellular responses were lost for the others. We thus concluded that a hydrogen bond acceptor was required to maintain binding to A q and T-cell responses, whereas the hydrogen bond donor of the amide bond could be omitted. The hydroxyethylene isosteres utilized in this study introduce a chiral centre and a hydrogen bond donor capability at the Ala 261 -Gly 262 position, while retaining the hydrogen bond acceptor capability.
Synthesis
The diastereomeric Ala 261 -Gly 262 hydroxyethylene isosteres were synthesized as dipeptide building blocks suitably protected for use in Fmoc-based solid-phase peptide synthesis (SPPS). 18 In short, ketomethylene derivative 5 14 was first diastereoselectively reduced to the respective alcohol, followed by protective group manipulations and separation of diastereomeric mixtures. obtained in 84% yield although with a disappointing 4S : 4R dr of 2 : 1. The diastereomeric mixture 7 was difficult to separate by column chromatography and therefore additional transformations were performed. Both 6 and 7 were deprotected using TFA to remove the Boc and tBu protecting groups followed by Fmoc protection, which produced the lactones 8 and 9 (4S : 4R of 2 : 1), respectively. The latter mixture of lactones was at this stage separated by chiral HPLC chromatography to afford 9 with a 4S : 4R dr of 99 : 1. In the final step, reaction with tBuSH-AlMe 3 converted the lactones into the corres- ponding γ-hydroxy thioesters that were immediately silylated with TBDMSCl to give 10 and 12 in order to prevent relactonization. 21 Finally, base-catalysed hydrolysis of the thioesters provided the target hydroxyethylene isostere building blocks 11 and 13. The isostere building blocks 11 and 13 were incorporated into the CII259-273 glycopeptide sequence using Fmoc-based SPPS 18 under standard conditions. The isosteric glycopeptides were cleaved from the solid support, deacetylated, and purified by reversed-phase HPLC to give the trifluoroacetate salts of 2 and 3 ( Fig. 1 ) with overall yields of 18 and 28%, respectively, and in >98% purity. All glycopeptides were homogeneous, according to analytical reversed-phase HPLC and their structures were confirmed by 1 H NMR spectroscopy and MALDI-TOF mass spectrometry.
Binding to the A q protein and recognition by T-cell hybridomas
The ability of the hydroxyethylene-modified glycopeptides 2 and 3 to bind to the A q protein compared to 1 was assessed in a competitive ELISA binding assay. Significant optimisation was undertaken to obtain a satisfactory signal to noise ratio in the ELISA, which led to the use of rather high concentrations of the biotinylated class II-associated invariant chain peptide (CLIP) tracer. As the CLIP binds with high affinity to A q higher concentrations of weaker inhibitors, such as native 1, had to be employed in the ELISA. No binding could be detected for 2 and 3 even at the highest concentration of 1 mM where 1 completely competed out of the biotinylated CLIP tracer (Fig. 3) . However, it is likely that a weak binding of 2 and 3 to A q would not be detected under the conditions that had to be employed in the ELISA. Replacement of the Ala 261 -Gly 262 amide bond with the two different hydroxyethylene isosteres thus had severe effects on the glycopeptide abilities to bind to A q . These results underscore our previous results that this particular amide bond is highly sensitive to modifications. At this position the corresponding ketomethylene-isostere 4 is the only modified glycopeptide so far that has been shown to bind equally well to A q as 1.
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The T-cell response was investigated in a cell-based assay, where IL-2 secretion of A q restricted T-cell hybridoma lines was measured after incubation with antigen-presenting spleen cells expressing A q and increasing concentrations of the glycopeptides 1, 2 or 3 (Fig. 4) . Four A q -restricted T-cell hybridomas that differed in their TCR specificity for the hydroxyl groups of the galactose moiety were investigated for their ability to recognize the glycopeptides. Despite the fact that no binding of 2 and 3 to A q was detected by the competition assay, both were recognized and stimulated IL-2 secretion by HCQ.3 and HM1R.2, while the other two hybridomas HCQ.10 and 22a1-7e did not give any response (Fig. 4) . The HCQ.3 and HM1R.2 responses of 2 and 3 were significantly weaker compared to the responses elicited by both the non-modified 1 and ketomethylene-isosteric glycopeptide 4; the latter of which elicited intermediate to strong responses from three of the four hybridomas. 14 This suggests that 2 and 3 do in fact bind to A q and were presented to the T-cell receptor in the functional assay, although too weakly to be detected in the binding assay. That HCQ.10 and 22a1-7e were more sensitive towards the introduced modifications in the backbone compared to HCQ.3 and HMIR.2 has also been seen in previous studies. 13, 14 Analysis of glycopeptide/A q -complexes by MD simulations Glycopeptides 1-4 were modelled into A q to understand if the structures of the complexes correlated with the binding affinity for A q and with the subsequent T cell responses. We found that the modified glycopeptides 2-4 displayed a binding mode almost identical to that of the native glycopeptide 1 in their respective complexes. Similar interactions were retained for all four glycopeptides although the position of the hydrogen bond acceptor had been altered for the hydroxylethylene-isosteric glycopeptides 2 and 3 compared to the carbonyl oxygen in 1 and 4. As the static structures were unable to explain the observed differences in A q binding and T cell responses the dynamics of the isostere modified glycopeptide/A q -complexes and the native system were studied over time using MD simulations. Repeated 60 ns MD simulations at different initial velocities were conducted for 1 (two times) and the modified glycopeptides 2-4 (three times) in a complex with A q , using the static models as starting structures. The repeated runs will hereafter be referred to as (I), (II) and (III) and can be seen as samples from the complete conformational landscape of the systems. In general, the simulations reached equilibrium after 40 ns according to the root-mean-square deviation (RMSD) values (see the ESI † for RMSD plots). The analyses of the MD simulations were then focused on the binding mode and flexibility of the glycopeptides, and the hydrogen bonding network between the modified glycopeptides and A q over the last 20 ns of the repeated runs. The system of 1/A q served as a reference to which the modified glycopeptides 2-4 have been compared. proved to be much more flexible and did not adopt a stable binding mode during the course of the simulations. This is consistent with previous MD simulations of the system, 10,13 as well as the fact that the minimal epitope required for binding to A q consists of the N-terminal octapeptide Ile 260 -Gln 267 .
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The S-and R-hydroxyethylene-isosteric glycopeptides 2 and 3 displayed a different dynamic pattern compared to 1, with large variations between the repeated MD simulations (Table 1 and ESI †). The S-hydroxyethylene-isostere 2 showed larger movements; the N-terminus of the glycopeptide was not as firmly anchored in the binding groove as for 1 and displayed a high degree of flexibility ( Fig. 5 and the ESI †). In fact, the anchor residue Phe 263 and occasionally also Ile 260 were leaving their respective binding pockets. In addition, a clear unfolding was observed in the β 1 -helix at the point of the modification of the peptide. The R-hydroxyethylene-isostere 3 also displayed larger flexibility; again both anchor residues were leaving their respective binding pockets and the β 1 -helix was unfolded adjacent to the isostere in 3 ( have not observed a behaviour similar to 2 and 3, with the peptide dissociating from the binding groove, anchor residues leaving the P1 and P4 pockets, or unfolding of the β 1 -helix.
Hydrogen bond network
An extensive hydrogen bond network anchored glycopeptide 1 into A q during the molecular dynamics simulations. In total, 13 different hydrogen bonds were observed between the backbone of 1 and A q , and 7 of these had over 40% occupancy during the simulation (Tables 1 and 2 ). The majority of hydrogen bonds were formed between the N-terminal part of 1 (Gly 259 -Gly 265 ) and A q , which was consistent with previous findings. 13, 14 In this sequence, 8 out of 13 intermolecular hydrogen bonds were present, of which 5 were considered strong bonds. In particular two hydrogen bonds showed a high presence during the MD simulations, Ala 261 (a)-Asn 82 (s) and Gln 267 (a)-Trp 61 (s) ( Table 2 ).
In the case of the modified glycopeptides 2 and 3, insertion of the hydroxyethylene isostere at the Ala 261 -Gly 262 position disturbed the overall hydrogen bond pattern during the MD simulations (Tables 1 and 2 ). Although hydrogen bonds could Table 2 ).
The pattern of strong hydrogen bonds observed for 4 was more consistent with the pattern seen in the complex of 1 and A q , despite the loss of hydrogen bond donation ability of Gly 262 (d);
a finding that agrees well with the observation that no hydrogen bond was formed with this residue in the MD simulations of native 1.
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The disrupted hydrogen bond networks seen in the dynamics analyses of 2 and 3, as compared with 1 and 4, resulted in the larger flexibility as seen for those glycopeptides and their dissociation from the binding groove of A q discussed in the previous section. It is also likely that the altered hydrogen bonding was connected to the unfolding of the β 1 -helix observed in the complexes of 2 and 3. Thus, the dynamics calculations point to the fact that loss of one important hydrogen bond has a tremendous effect on both the structure and the stability of the entire complex. This loss most likely explains the dramatic difference in binding to A q between isosteres 2 and 3 and native 1 as seen in the competitive binding assay. Retention of the hydrogen bond between Gln 267 (a)-Trp 61 (s), which has a high occupancy for all four glycopeptides (Table 2) , may explain the weak binding of 2 and 3 to A q as revealed by the stimulation of two of the four T cell hybridomas.
In conclusion, the MD-simulations displayed a far more detailed picture than the static models, and emphasized the importance of studying the dynamics to understand the behaviour and evolution over time of the A q -glycopeptide complexes. While the binding mode for the native glycopeptide 1 and the ketomethylene-isosteric glycopeptide 4 was similar to the static model, the hydroxyethylene-isosteres 2 and 3 displayed a behaviour deviating from what could be seen in static models. Studies of the dynamics of A q -glycopeptide complexes, but not static models, were therefore crucial to explain the results from the in vitro studies of class II MHC binding and T cell recognition.
Alteration of the epitope presented to the T cell
As described above, the T-cell response patterns elicited by the modified glycopeptides 2 and 3 differed from that of 1, being reduced for two hybridomas and not detectable for the other two. A reduced or eliminated T-cell response may be due to either a weaker binding to A q , and/or that the epitope presented to the TCR has been changed. We conclude that the finding that two of the hybridomas respond weakly to 2 and 3, while the other two do not respond at all, suggests that both effects are in operation. This conclusion is further supported amide bond with hydroxyethylene-isosteres disrupted the hydrogen bond network in the complexes. This, in turn, led to the altered structure and dynamics and explains the dramatic effects on the A q binding and the T cell recognition.
Experimental section
Chemistry
General. All reactions were performed under an inert atmosphere with dry solvents under anhydrous conditions, unless otherwise stated. TLC was performed on Silica Gel 60 F 254 (Merck) with detection by using UV light and staining with alkaline aqueous KMnO 4 followed by heating. After workup, organic solutions were dried over Na 2 SO 4 (4S/R,5S)-5-tert-Butoxycarbonylamino-4-hydroxy-hexanoic acid tert-butyl ester (7). Ketone 5 (269 mg, 0.892 mmol) was dissolved in dry THF (22 mL) and cooled to −78°C followed by dropwise addition of (S)-alpine-hydride (0.5 M in THF, 1.96 mL, 0.980 mmol). After stirring for 80 min at −78°C, citric acid (10%, aq.) was added and the mixture was allowed to reach rt followed by the addition of Et 2 O and brine. The aqueous phase was extracted with Et 2 O and the combined organic layers were dried and concentrated under reduced pressure. The crude was purified by flash chromatography (n-heptane/EtOAc 5 : 1 → 2 : 1) to afford 7 (4S : 4R 2 : 1, 227 mg, 84%) as a colorless oil. (12) . Alcohol 6 (137 mg, 0.452 mmol) dissolved in CH 2 Cl 2 (2.2 mL) was treated with TFA (0.9 mL) at rt for 24 h. The solution was concentrated under reduced pressure, the resulting residue was concentrated from CHCl 3 three times and was thereafter dissolved in dioxane (2.2 mL) and H 2 O (0.8 mL). FmocOSu (187 mg, 0.542 mmol) was added and the mixture was cooled to 0°C followed by dropwise addition of Na 2 CO 3 (58 mg, 0.542 mmol) dissolved in H 2 O (0.35 mL). The mixture was allowed to reach rt and was stirred for 24 h before dioxane was removed under reduced pressure. CHCl 3 and H 2 O were added and the aqueous phase was acidified by the addition of HCl (10%, aq.) at 0°C to pH 1. The phases were separated and the aqueous phase was extracted with CHCl 3 . The combined organic layers were washed with brine, dried and concentrated under reduced pressure. The resulting crude was purified by flash chromatography (nheptane/EtOAc/AcOH 2 : 1 : 1% → 1 : 1 : 1%) to afford 8 (136 mg, 86%). (5S)-5-[(1S/R)-1-(9H-Fluoren-9-ylmethoxycarbonylamino)-ethyl]-dihydro-furan-2-one (9). Alcohol 7 (188 mg, 0.621 mmol) dissolved in CH 2 Cl 2 (3.0 mL) was treated with TFA (1.3 mL) at rt for 19 h. The solution was concentrated under reduced pressure, the resulting residue was concentrated from CHCl 3 three times and was thereafter dissolved in dioxane (3.0 mL) and H 2 O (1.2 mL). FmocOSu (257 mg, 0.746 mmol) was added and the mixture was cooled to 0°C followed by dropwise addition of Na 2 CO 3 (79 mg, 0.746 mmol) dissolved in H 2 O (0.3 mL). The mixture was allowed to reach rt and was stirred for 22 h before dioxane was removed under reduced pressure. H 2 O and CHCl 3 were added, the phases were separated and the aqueous phase was extracted with CHCl 3 . The combined organic layers were washed with brine, dried and concentrated under reduced pressure. The resulting crude was purified by flash chromatography (n-heptane/EtOAc 2 : 1 → 1 : 1) followed by purification by chiral preparative HPLC (Chiralpak AD column, 250 × 20 mm, 5 μm, with n-heptane/EtOH 70 : 30 as the eluent, 18 mL min −1 flow rate and UV detection at 300 nm) to afford 9 (4S : 4R 99 : 1, 108 mg, 48% (4R,5S)-4-(tert-Butyl-dimethyl-silanyloxy)-5-(9H-fluoren-9-ylmethoxycarbonylamino)-hexanethioic acid tert-butyl ester (10) . AlMe 3 (1 M in heptane, 2.50 mL, 2.50 mmol) was added dropwise to a solution of t-BuSH (0.28 mL, 2.53 mmol) in CH 2 Cl 2 (3.6 mL) at 0°C. The mixture was stirred for 10 min at 0°C, 10 min at rt followed by 10 min at 0°C. Lactone 8 (106 mg, 0.301 mmol) dissolved in CH 2 Cl 2 (1.9 m L) was added dropwise followed by stirring for 3 h and 30 min at 0°C. The reaction was cooled to −78°C and Et 2 O (11 mL) was added followed by dropwise addition of HCl (1 M, 3 mL). The resulting mixture was then stirred for 10 min before it was allowed to reach 0°C. The workup was performed under cold conditions to prevent relactonization using ice-cold solvent and aqueous solutions. After addition of Et 2 O and HCl (1 M), the layers were separated, and the aqueous layer was extracted with Et 2 O. The combined organic layers were washed with HCl (1 M, aq.), NaHCO 3 (satd, aq.) and brine, dried and concentrated under reduced pressure under cold conditions. The resulting crude product was mixed with TBDMSCl (197 mg 1.27 mmol) and imidazole (173 mg, 2.54 mmol), and dissolved in DMF (0.27 mL). After stirring for 20 h and 30 min at rt, NaHCO 3 was added followed by the addition of H 2 O and CH 2 Cl 2 . The phases were separated and the aqueous layer was extracted with CH 2 Cl 2 . The combined organic layers were washed with H 2 O and brine, dried, and concentrated under reduced pressure. Purification by flash chromatography twice (first using n-heptane/EtOAc 8 : 1, then using n-heptane/EtOAc 1 : 0 → 8 : 1) gave 10 (93 mg, 55%) as a colorless oil. (4S,5S)-4-(tert-Butyl-dimethyl-silanyloxy)-5-(9H-fluoren-9-ylmethoxycarbonylamino)-hexanethioic acid tert-butyl ester (12) . AlMe 3 (2 M in heptane, 1.15 mL, 2.30 mmol) was added dropwise to a solution of t-BuSH (0.26 mL, 2.31 mmol) in CH 2 Cl 2 (2.5 mL) at 0°C. The mixture was stirred for 10 min at 0°C, 10 min at rt followed by 10 min at 0°C. Lactone 9 (96 mg, 0.273 mmol) dissolved in CH 2 Cl 2 (3.5 mL) was added dropwise followed by stirring for 3 h at 0°C. The solution was cooled to −78°C and Et 2 O (10 mL) was added followed by dropwise addition of HCl (1 M, 2.7 mL). The resulting mixture was then stirred for 10 min before it was allowed to reach 0°C. The workup was performed using ice-cold solvent and aqueous solutions to prevent relactonization. After addition of Et 2 O and HCl (1 M), the phases were separated, and the aqueous layer was extracted with Et 2 O. The combined organic layers were washed with HCl (1 M, aq.), NaHCO 3 (satd, aq.) and brine, dried and concentrated under reduced pressure and cold conditions. The resulting crude product was immediately mixed with TBDMSCl (182 mg 1.20 mmol) and imidazole (157 mg, 2.30 mmol) and dissolved in DMF (1.0 mL). After stirring for 16 h at rt, NaHCO 3 (aq., satd.) was added followed by the addition of H 2 O and CH 2 Cl 2 . The phases were separated and the aqueous layer was extracted with CH 2 Cl 2 . The combined organic layers were washed with H 2 O and brine, dried, and concentrated under reduced pressure. Purification by flash chromatography (n-heptane/EtOAc 1 : 0 → 8 : 1) gave 12 (102 mg, 85%) as a colorless oil. (4R,5S)-4-(tert-Butyl-dimethyl-silanyloxy)-5-(9H-fluoren-9-ylmethoxycarbonylamino)-hexanoic acid (11) . A premixed solution of H 2 O 2 (30% aq. solution, 2.70 mL) and LiOH (0.2 M, 1.38 mL, 0.276 mmol) was added dropwise to 10 (81 mg, 0.145 mmol) dissolved in THF (10 mL) at 0°C. The mixture was allowed to reach rt followed by stirring for 3.5 h and then it was cooled to 0°C. Na 2 SO 3 (2 M, 5 mL) was added dropwise followed by stirring for 40 min at 0°C. The mixture was acidified by the addition of HCl (10%, aq.), Et 2 O was added, the phases were separated and the aqueous layer was extracted with Et 2 O. The combined organic layers were washed with NaHCO 3 (satd, aq.), dried and concentrated under reduced pressure. Purification by flash chromatography (n-heptane/EtOAc/AcOH 6 : 1 : 1% (4S,5S)-4-(tert-Butyl-dimethyl-silanyloxy)-5-(9H-fluoren-9-ylmethoxycarbonylamino)-hexanoic acid (13) . A premixed solution of H 2 O 2 (30% aq., 3.0 mL) and LiOH (0.2 M, 1.5 mL, 0.300 mmol) was added dropwise to 12 (91 mg, 0.165 mmol) in THF (11 mL) at 0°C. The mixture was allowed to reach rt followed by stirring for 3.5 h and then it was cooled to 0°C. Na 2 SO 3 (2 M, 5.6 mL) was added dropwise followed by stirring for 40 min at 0°C. The mixture was acidified by addition of HCl (10% aq.), Et 2 O was added, the phases were separated and the aqueous phase was extracted with Et 2 O. The combined organic layers were washed with NaHCO 3 (satd, aq.), dried and concentrated under reduced pressure. Purification by flash chromatography (n-heptane/EtOAc/ General procedure for solid-phase peptide synthesis. Glycopeptides 2 and 3 were synthesized in mechanically agitated reactors on a TentaGel-S-PHB-Thr(tBu)-Fmoc resin (40 μmol) using standard solid-phase methodology essentially as described elsewhere. 25 All couplings were performed in DMF. 14, 26 (1.5 equiv.) and the isostere building blocks 11 and 13 (1.5 equiv.) were activated with 7-aza-1-hydroxybenzotriazole (HOAt, 3 equiv.) and DIC (1.5 equiv.) and coupled for 24 h. Fmoc deprotection after each coupling cycle was accomplished by treatment with 20% piperidine in DMF for 10 min. The glycopeptides were cleaved from the resin with trifluoroacetic acid/H 2 O/thioanisole/ethanedithiol (35 : 2 : 2 : 1, 40 mL) for 3 h at 40°C with workup performed essentially as described elsewhere. 25 Purification by reversed-phase HPLC was followed by deacetylation with NaOMe in MeOH (20 mM, 1 mL per mg peptide) for 2-3 h at rt (monitored by analytical reversed-phase HPLC). The mixture was neutralized by addition of AcOH and concentrated under reduced pressure, and the residue was finally purified using reversed-phase HPLC followed by lyophilization. (2) . Synthesis was performed with building block 13 according to the general procedure described above. This afforded the trifluoroacetate salt of 2 (12.4 mg, 18% yield based on the amount of resin used) as a white amorphous solid after lyophilization. MS (MALDI-TOF) calcd 1654.82 for [M + H] + , found 1654.82. 1 H NMR data are given in Table 3 . Table 4 .
A q binding assay
The abilities of the backbone-modified glycopeptides 2 and 3 and non-modified CII259-273 1 4 to bind to A q were determined relative to a biotinylated CLIP peptide with a competitive inhibition assay performed using 96-well microtiter assay plates essentially as described elsewhere. 9, 27 Briefly, purified soluble recombinant A q proteins (1 μM) expressed in Drosophila melanogaster SL2 cells were incubated with a fixed concentration of the CLIP-bio (3 μM, sequence KPVSKMRMATPLLMQALPM) and increasing concentrations of test peptides 1, 2 and 3 (0, 0.98, 1.95, 3.91, 7.81, 15.63, 32.25, 62.5, 125, 250, 500 and 1000 μM) in PBS for 48 h at room temperature. This mixture also contained a cocktail of protease inhibitors (Complete™, Boehringer, Mannheim). During this incubation, new 96-well microtiter assay plates were precoated with Y3P monoclonal antibodies (mAb) (10 μg mL −1 ) by incubation overnight at 4°C followed by blocking with PBS containing 2% low fat milk and washing with PBS containing 0.1% Tween 20. The incubated mixtures containing A q proteins, CLIP-bio, and test peptides (90 μL) were transferred to the plates precoated with mAb followed by incubation overnight at 4°C. After washing with PBS (0.1% Tween 20) the amount of CLIP-bio bound to the A q proteins captured by the mAb in the wells was quantified using the dissociationenhanced lanthanide fluoroimmunoassay (DELFIA®) system based on the time-resolved fluoroimmunoassay technique with europium labeled streptavidin (Wallac, Turku), according to the manufacturer's instructions. The experiments were performed in duplicates.
T-cell activation assays
Responses of the A q restricted T-cell hybridoma lines (i.e., the amount of IL-2 secreted following incubation of the hybridoma with antigen-presenting spleen cells expressing A q and increasing concentrations of the glycopeptides) were determined essentially as described elsewhere, 28 with slight modifications. 
Molecular modelling
Preparation of the complexes. The initial coordinates for A q in a complex with 1 were obtained from an X-ray crystal structure 22 and prepared using the Protein Preparation Wizard 30 in
Maestro. 31 Bond orders were assigned, hydrogens added, disulfide bonds created, termini were capped, and no water molecules were included. 
